Procter&Gamble Healt

₹4709.8 49.4 | 1.1%

WEBSITE BSE:500126 NSE : PGHL 10 May, 16:01

Market Cap ₹7818 Cr.

Stock P/E 36.5

P/B 9.2

Current Price ₹4709.8

Book Value ₹ 513.5

Face Value 10

52W High ₹5640

Dividend Yield 2.02%

52W Low ₹ 4600

Edit Ratio

Procter&Gamble Healt Research see more...

Overview Inc. Year: 1967Industry: Pharmaceuticals & Drugs

Procter & Gamble Health Ltd is an India-based corporation that is frequently engaged within the manufacturing of pharmaceutical products. The Company gives healthcare merchandise. It is concerned in production and advertising over-the-counter vitamins, minerals, and supplements merchandise for a healthy life-style. The Company offers brands, consisting of Cosome, Neurobion, Livogen, SevenSeas, Evion, Polybion and Nasivion. The Company’s geographical segments consist of both in India and out of India. It has its production facility situated at Usgaon, Goa. The Company has a sterile facility with a ability of approximately 260 Mio ampoules/annum and a smooth gel production site with a capability of over 744 Mio capsules/annum. Its production site also exports to approximately 13 international locations inside P&G Personal Healthcare International.

Procter&Gamble Healt Share Price

New

Volume

Price

Price: NSE50 DMA200 DMAVolume

Quarterly Price

Quarterly Monthly

Show Value Show %

Peer Comparison

Procter&Gamble Healt Quarterly Results

#(Fig in Cr.)	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024
Net Sales	278	268	296	298	310	321	301	305	310	252
Other Income	5	2	3	3	5	5	5	6	5	2
Total Income	283	270	299	301	315	326	307	311	315	255
Total Expenditure	216	199	237	207	201	241	256	216	208	185
Operating Profit	67	71	62	94	113	85	51	95	107	70
Interest	0	0	0	0	0	0	0	0	0	0
Depreciation	7	6	7	7	8	6	7	6	7	7
Exceptional Income / Expenses	0	0	0	0	0	0	0	0	0	0
Profit Before Tax	60	65	55	87	105	79	44	88	100	63
Provision for Tax	15	14	13	23	28	19	14	22	28	16
Profit After Tax	45	51	41	64	77	59	30	66	72	47
Adjustments	0	0	0	0	0	0	0	0	0	0
Profit After Adjustments	45	51	41	64	77	59	30	66	72	47
Adjusted Earnings Per Share	27	30.8	24.8	38.3	46.3	35.7	18	39.5	43.4	28

Procter&Gamble Healt Profit & Loss

#(Fig in Cr.)	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Jun 2020	Jun 2021	Jun 2022	Jun 2023	TTM
Net Sales	687	798	867	940	993	698	849	1356	1009	1114	1230	1168
Other Income	20	21	20	23	24	30	28	70	18	13	18	18
Total Income	707	819	888	963	1017	729	877	1426	1027	1128	1248	1188
Total Expenditure	582	721	809	856	877	628	705	1042	763	847	905	865
Operating Profit	126	98	79	107	140	101	173	384	264	281	343	323
Interest	0	0	0	0	0	0	0	0	1	0	1	0
Depreciation	9	10	13	23	25	19	21	29	30	27	28	27
Exceptional Income / Expenses	0	0	0	0	0	17	7	0	0	0	0	0
Profit Before Tax	117	88	67	83	115	99	158	355	233	253	314	295
Provision for Tax	38	32	23	30	36	38	56	101	56	61	85	80
Profit After Tax	78	56	43	54	79	61	102	254	177	193	229	215
Adjustments	0	0	0	0	0	33	737	0	0	0	0	0
Profit After Adjustments	78	56	43	54	79	94	839	254	177	193	229	215
Adjusted Earnings Per Share	47.2	33.7	26	32.3	47.7	36.8	61.3	153.1	106.5	116	138.2	128.9

Growth Rates

#	1 Year	3 Year	5 Year	10 Year
Sales CAGR	10%	-3%	12%	6%
Operating Profit CAGR	22%	-4%	28%	11%
PAT CAGR	19%	-3%	30%	11%

#	1 Year	3 Year	5 Year	10 Year
Share Price CAGR	-0%	-7%	5%	22%
ROE Average	34%	28%	23%	17%
ROCE Average	46%	38%	31%	24%

Procter&Gamble Healt Balance Sheet

#(Fig in Cr.)	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Jun 2020	Jun 2021	Jun 2022	Jun 2023
Shareholder's Funds	484	523	554	592	664	733	1540	906	704	616	751
Minority's Interest	0	0	0	0	0	0	0	0	0	0	0
Borrowings	0	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	338	13	390	395	399	431	495	667	723	714	803
Total Current Liabilities	195	237	260	539	301	352	548	539	551	608	679
Total Liabilities	1016	773	1204	1525	1363	1516	2583	2112	1978	1938	2233
Fixed Assets	75	85	110	132	111	115	100	98	101	109	142
Other Non-Current Assets	385	86	471	448	502	522	594	749	838	845	920
Total Current Assets	557	602	623	946	750	879	1889	1265	1039	984	1171
Total Assets	1016	773	1204	1525	1363	1516	2583	2112	1978	1938	2233

Procter&Gamble Healt Cash Flow

#(Fig in Cr.)	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Jun 2020	Jun 2021	Jun 2022	Jun 2023
Opening Cash & Cash Equivalents	31	4	7	5	9	26	10	1119	636	464	319
Cash Flow from Operating Activities	54	0	5	83	107	54	-130	235	247	170	236
Cash Flow from Investing Activities	-82	7	11	-68	-75	-48	1270	165	-32	-26	-22
Cash Flow from Financing Activities	0	-5	-17	-12	-15	-22	-30	-883	-387	-289	-98
Net Cash Inflow / Outflow	-28	3	-1	4	17	-16	1109	-483	-172	-145	116
Closing Cash & Cash Equivalent	4	7	5	9	26	10	1119	636	464	319	435

Procter&Gamble Healt Ratios

#	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Jun 2020	Jun 2021	Jun 2022	Jun 2023
Earnings Per Share (Rs)	47.23	33.66	26.04	32.27	47.67	36.77	61.29	153.06	106.51	115.98	138.23
CEPS(Rs)	52.59	39.73	33.67	46.37	62.61	48.29	74.01	170.8	124.6	132.29	155.16
DPS(Rs)	2.5	8.5	6	7.5	11	15	440	230	130	52.5	95
Book NAV/Share(Rs)	291.36	315.08	333.92	356.36	399.89	441.72	927.78	544.82	421.59	366.99	447.62
Core EBITDA Margin(%)	14.86	9.31	6.56	8.57	11.22	9.93	16.98	23.18	24.39	22.73	24.44
EBIT Margin(%)	16.45	10.68	7.41	8.56	11.18	13.9	18.61	26.17	23.21	21.55	23.71
Pre Tax Margin(%)	16.45	10.68	7.41	8.56	11.18	13.9	18.61	26.17	23.13	21.51	23.66
PAT Margin (%)	11.04	6.76	4.81	5.5	7.68	8.58	11.98	18.74	17.53	16.35	17.28
Cash Profit Margin (%)	12.3	7.98	6.23	7.9	10.09	11.27	14.47	20.91	20.5	18.64	19.39
ROA(%)	8.16	6.25	4.37	3.92	5.48	4.24	4.96	10.82	8.65	9.83	11
ROE(%)	17.54	11.1	8.02	9.35	12.61	8.74	8.95	20.79	22.04	29.41	33.94
ROCE(%)	26.14	17.53	12.36	14.54	18.35	14.16	13.9	29.01	29.08	38.45	46.07
Receivable days	32.54	32.82	38.34	43.3	41.4	58.92	40.59	21.73	28.06	22.2	27.36
Inventory Days	62.74	62.47	66.9	64.49	58.63	82.51	58.27	33.31	45.68	36.19	34.37
Payable days	39.16	36.72	35.42	44.71	61.19	118.32	116.16	90.99	177.09	188.51	206.35
PER(x)	13.76	16.67	30.53	24.14	20.93	35.05	50.32	26.57	52.52	36.1	37.97
Price/Book(x)	2.23	1.78	2.38	2.19	2.49	2.92	3.32	7.47	13.27	11.41	11.73
Dividend Yield(%)	0.38	1.51	0.75	0.96	1.1	1.16	14.27	5.65	2.32	1.25	1.81
EV/Net Sales(x)	1.29	0.93	1.33	1.18	1.39	2.67	4.57	4.51	8.74	5.95	6.73
EV/Core EBITDA(x)	7.05	7.57	14.58	10.35	9.83	18.42	22.47	15.91	33.38	23.59	24.12
Net Sales Growth(%)	16.57	16.08	8.74	8.3	5.65	-29.66	21.61	59.7	-25.6	10.48	10.34
EBIT Growth(%)	22.04	-24.44	-24.58	25.2	38.21	-14.11	59.7	124.62	-34.03	8.42	24.11
PAT Growth(%)	23.12	-28.72	-22.66	23.92	47.74	-22.86	66.68	149.73	-30.42	8.89	19.19
EPS Growth(%)	23.12	-28.72	-22.66	23.92	47.74	-22.86	66.68	149.73	-30.42	8.89	19.19
Debt/Equity(x)	0	0	0	0	0	0	0	0	0	0	0
Current Ratio(x)	2.85	2.55	2.4	1.76	2.5	2.5	3.45	2.35	1.89	1.62	1.72
Quick Ratio(x)	2.18	1.9	1.72	1.45	1.95	2.05	3.24	2.1	1.67	1.43	1.53
Interest Cover(x)	0	0	0	0	0	0	0	0	292.6	604.26	409.05
Total Debt/Mcap(x)	0	0	0	0	0	0	0	0	0	0	0

Procter&Gamble Healt Shareholding Pattern

#	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024
Promoter	51.82	51.82	51.82	51.82	51.82	51.82	51.82	51.82	51.82	51.82
FII	5.97	6.57	6.47	6.05	6.33	6.72	7.15	7.38	7.59	6.24
DII	8.53	7.9	8.07	12.62	12.43	12.32	12.3	12.31	12.67	13.73
Public	33.69	33.71	33.64	29.46	29.42	29.15	28.74	28.49	27.92	28.21
Others	0	0	0	0.06	0	0	0	0	0	0
Total	100	100	100	100	100	100	100	100	100	100

#	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024
Promoter	0.86	0.86	0.86	0.86	0.86	0.86	0.86	0.86	0.86	0.86
FII	0.1	0.11	0.11	0.1	0.11	0.11	0.12	0.12	0.13	0.1
DII	0.14	0.13	0.13	0.21	0.21	0.2	0.2	0.2	0.21	0.23
Public	0.56	0.56	0.56	0.49	0.49	0.48	0.48	0.47	0.46	0.47
Others	0	0	0	0	0	0	0	0	0	0
Total	1.66	1.66	1.66	1.66	1.66	1.66	1.66	1.66	1.66	1.66

Pros

Company has delivered good profit growth of 30% CAGR over last 5 years
Company has a good return on equity (ROE) track record: 3 Years ROE 28%
Company is almost debt free.

Cons

Debtor days have increased from 188.51 to 206.35days.
Stock is trading at 9.2 times its book value.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Procter&Gamble Healt News

IPO

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Procter&Gamble Healt

Add Watchlist

Procter&Gamble Healt Research see more...

Overview Inc. Year: 1967Industry: Pharmaceuticals & Drugs

Procter&Gamble Healt Share Price

Alert Data

Quarterly Price

Peer Comparison

Procter&Gamble Healt Quarterly Results

Procter&Gamble Healt Profit & Loss

Growth Rates

Procter&Gamble Healt Balance Sheet

Procter&Gamble Healt Cash Flow

Procter&Gamble Healt Ratios

Procter&Gamble Healt Shareholding Pattern

Procter&Gamble Healt News

IPO

Stocx: India's #1 Marketplace to Find Your Winning Stock

Please Login!

Error!